These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 18167366)

  • 1. Weighing up the cardiovascular benefits of thiazolidinedione therapy: the impact of increased risk of heart failure.
    Erdmann E; Wilcox RG
    Eur Heart J; 2008 Jan; 29(1):12-20. PubMed ID: 18167366
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Heart failure with thiazolidinedione treatment: what do we know today?].
    Erdmann E
    Dtsch Med Wochenschr; 2009 Jan; 134(4):154-8. PubMed ID: 19148858
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk of hospitalization for heart failure associated with thiazolidinedione therapy: a medicaid claims-based case-control study.
    Hartung DM; Touchette DR; Bultemeier NC; Haxby DG
    Pharmacotherapy; 2005 Oct; 25(10):1329-36. PubMed ID: 16185176
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thiazolidinediones in type 2 diabetes: a cardiology perspective.
    Khanderia U; Pop-Busui R; Eagle KA
    Ann Pharmacother; 2008 Oct; 42(10):1466-74. PubMed ID: 18698014
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thiazolidinedione insulin sensitizers and the heart: a tale of two organs?
    Buckingham RE; Hanna A
    Diabetes Obes Metab; 2008 Apr; 10(4):312-28. PubMed ID: 18333890
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pioglitazone and cardiovascular risk. A comprehensive meta-analysis of randomized clinical trials.
    Mannucci E; Monami M; Lamanna C; Gensini GF; Marchionni N
    Diabetes Obes Metab; 2008 Dec; 10(12):1221-38. PubMed ID: 18505403
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Glitazones and congestive heart failure: update on PROactive, ADOPT, DREAM and RECORD clinical trials].
    De Flines J; Scheen AJ
    Rev Med Suisse; 2007 Aug; 3(122):1876, 1878-83. PubMed ID: 17896661
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thiazolidinediones and congestive heart failure: a judicious balance of risks and benefits.
    Patel RR
    Cardiol Rev; 2009; 17(3):132-5. PubMed ID: 19384087
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. October 7, 2003.
    Nesto RW; Bell D; Bonow RO; Fonseca V; Grundy SM; Horton ES; Le Winter M; Porte D; Semenkovich CF; Smith S; Young LH; Kahn R; ;
    Circulation; 2003 Dec; 108(23):2941-8. PubMed ID: 14662691
    [No Abstract]   [Full Text] [Related]  

  • 10. Tolerability outcomes of a multicenter, observational, open-label, drug-surveillance study in patients with type 2 diabetes mellitus treated with pioglitazone for 2 years.
    Grossman LD; Parlan G; Bailey AL; Yee G; Yu M; Chan JY
    Clin Ther; 2009 Jan; 31(1):74-88. PubMed ID: 19243708
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Meta-analysis of rare events: an update and sensitivity analysis of cardiovascular events in randomized trials of rosiglitazone.
    Dahabreh IJ; Economopoulos K
    Clin Trials; 2008; 5(2):116-20. PubMed ID: 18375649
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The rough road for rosiglitazone.
    Goldfine AB
    Curr Opin Endocrinol Diabetes Obes; 2008 Apr; 15(2):113-7. PubMed ID: 18316944
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Thiazolidinediones in type 2 diabetes--have they lived up to expectations?
    Bhansali A; Modi P
    J Indian Med Assoc; 2005 Jun; 103(6):343-6. PubMed ID: 16225162
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thiazolidinediones and heart failure: a teleo-analysis.
    Singh S; Loke YK; Furberg CD
    Diabetes Care; 2007 Aug; 30(8):2148-53. PubMed ID: 17536074
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Type 2 diabetes mellitus and heart failure.
    Choy CK; Rodgers JE; Nappi JM; Haines ST
    Pharmacotherapy; 2008 Feb; 28(2):170-92. PubMed ID: 18225964
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk of heart failure in patients with recent-onset type 2 diabetes: population-based cohort study.
    Leung AA; Eurich DT; Lamb DA; Majumdar SR; Johnson JA; Blackburn DF; McAlister FA
    J Card Fail; 2009 Mar; 15(2):152-7. PubMed ID: 19254675
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thiazolidinediones: effects on the development and progression of type 2 diabetes and associated vascular complications.
    Krentz A
    Diabetes Metab Res Rev; 2009 Feb; 25(2):112-26. PubMed ID: 19219860
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thiazolidinedione drugs and cardiovascular risks: a science advisory from the American Heart Association and American College Of Cardiology Foundation.
    Kaul S; Bolger AF; Herrington D; Giugliano RP; Eckel RH; ;
    J Am Coll Cardiol; 2010 Apr; 55(17):1885-94. PubMed ID: 20413044
    [No Abstract]   [Full Text] [Related]  

  • 19. Thiazolinediones and heart failure: the potential to precipitate irreversible cardiac dysfunction.
    Iqbal MB; Fisher NG; Lyne JC; McDonagh TA
    Int J Cardiol; 2008 Jan; 123(2):e35-7. PubMed ID: 17320219
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Balancing risk and benefit with oral hypoglycemic drugs.
    Hamnvik OP; McMahon GT
    Mt Sinai J Med; 2009 Jun; 76(3):234-43. PubMed ID: 19421967
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.